Oragenics Inc. filings document the regulatory record of a clinical-stage biotechnology company focused on intranasal CNS therapeutics. The company’s 8-K reports include clinical and regulatory disclosures for ONP-002, including materials related to its Phase IIa program for concussion and mild traumatic brain injury, along with Regulation FD presentations and other public updates.
The filing record also covers capital-structure matters such as at-the-market common stock sales arrangements, shareholder meeting and proposal deadlines, executive compensation and equity awards, governance matters, risk factors, operating results and financial-condition disclosures, including going-concern language in the annual report.
Oragenics, Inc. received a Schedule 13G filing showing that Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz together report beneficial ownership of 412,654 shares of Oragenics common stock. This position represents 9.9% of the outstanding common shares as of the filing. The reporting persons state they have shared voting and dispositive power over all 412,654 shares and no sole voting or dispositive power. They also certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Oragenics, but instead are held on a passive basis consistent with a Schedule 13G filing.
Oragenics, Inc. filed a current report to share that it will use an updated investor presentation, dated January 20, 2026, in a presentation by its CEO at the Sequire Investor Summit. The same presentation, furnished as Exhibit 99.1, will also be available on the company’s website under the “Presentations” tab in the “News and Media” section. The company notes that this information is being furnished under Regulation FD and is not deemed “filed” for liability purposes under the Exchange Act unless specifically stated otherwise.
Oragenics, Inc. reported an equity award to its CEO and CFO, Janet Huffman. On 12/11/2025 she was granted an employee stock option to buy 250,000 shares of Oragenics common stock at an exercise price of $0.93 per share under the Company's 2021 Equity Incentive Plan, as amended.
One third of the options vest on the first anniversary of the grant date, with the remaining two thirds vesting in equal annual installments on the second and third anniversaries, provided she continues to perform services for the company through each vesting date. The options are scheduled to expire on 12/11/2035, and the exercise price was set at the closing price of the common stock on the grant date.
Oragenics Inc. reported that director Natasha Giordano received two stock option awards under the company’s 2021 Equity Incentive Plan on December 11, 2025. One non-employee director option covers 38,320 shares of common stock at an exercise price of $1.03, granted as an initial equity award upon her appointment to the board, and it vests immediately. A second option covers 125,000 shares at an exercise price of $0.93, also under the non-employee director compensation program, and it vests immediately as well. Both option grants are exercisable from December 11, 2025 and expire on December 11, 2035, and are held directly.
Oragenics Inc. director Fred Telling reported a small sale of company stock and a new stock option grant. On 12/12/2025, he sold 210 shares of common stock at a weighted average price of $0.9446 per share, leaving him with 34,538 shares of Oragenics common stock held directly.
On 12/11/2025, he received a non-employee director option award for 125,000 shares of Oragenics common stock under the company’s 2021 Equity Incentive Plan. The options have an exercise price of $0.93 per share, vest immediately on the grant date, and are scheduled to expire on 12/11/2035.
Oragenics Inc (OGEN) reported a grant of non-employee director stock options to director John Gandolfo. On 12/11/2025 he received options to purchase 125,000 shares of common stock at an exercise price of $ 0.93, with an expiration date of 12/11/2035.
The award was made under Oragenics' 2021 Equity Incentive Plan, as amended, pursuant to its non-employee director compensation program. The options vest immediately, and Gandolfo beneficially holds 125,000 derivative securities directly following this transaction.
Oragenics director Alan Dunton reported receiving an award of 125,000 options to buy the company’s common stock at an exercise price of $0.93 per share on 12/11/2025.
The options were granted under the company’s 2021 Equity Incentive Plan, as amended, pursuant to its non-employee director compensation program. They vest immediately, are exercisable starting 12/11/2025, and expire on 12/11/2035. Following this grant, 125,000 derivative securities are beneficially owned directly.
Oragenics Inc reported that director Robert Koski received a grant of stock options on 12/11/2025 under the company's 2021 Equity Incentive Plan, as amended, pursuant to its non-employee director compensation program. The option covers 125,000 shares of common stock at an exercise price of $0.93 per share, equal to the closing price on the grant date. The options vest immediately, are exercisable starting 12/11/2025, and expire on 12/11/2035. Following this award, Koski beneficially owns 125,000 stock options directly.
Oragenics Inc. reported that director Charles Pope received an award of stock options as part of the company’s non-employee director compensation program. On 12/11/2025 he was granted options to buy 125,000 shares of common stock at an exercise price of $0.93 per share under the company’s 2021 Equity Incentive Plan, as amended.
The options vest immediately, making them fully exercisable from the grant date, and they expire on 12/11/2035. After this grant, Pope beneficially owns 125,000 derivative securities directly, each representing the right to purchase one share of Oragenics common stock.
Oragenics, Inc. updated compensation for its leadership. The board increased Chief Executive Officer Janet Huffman’s annual base salary by five percent from $325,000 to $341,250, effective January 1, 2026, and awarded her a cash bonus of $110,500 based on performance under the existing compensation program.
The board also granted Huffman stock options to purchase 250,000 shares of common stock at an exercise price of $0.93 per share, vesting in equal annual installments over three years, with earlier vesting upon a change in control. Each non-employee director received options for 125,000 shares at $0.93 per share that vested immediately, and director Natasha Giordano received an additional onboarding stock option award valued at $30,000 when she joined the board.